Etomidate infusion at low doses is an effective and safe treatment for severe Cushing’s syndrome outside intensive care

in European Journal of Endocrinology

Correspondence should be addressed to D Maiter; Email: dominique.maiter@uclouvain.be
Restricted access

Introduction

Intravenous etomidate infusion is effective to rapidly lower cortisol levels in severe Cushing’s syndrome (CS) in the intensive care unit (ICU). Recently, etomidate treatment has also been proposed at lower doses in non-ICU wards, but it is not yet clear how this approach compares to ICU treatment.

Methods

We compared data from patients with severe CS treated with high starting doses of etomidate (median: 0.30 mg/kg BW/day) in ICU or with lower starting doses (median: 0.025 mg/kg BW/day) in non-ICU medical wards.

Results

Fourteen patients were included, among which ten were treated with low starting doses (LD) and four with high starting doses etomidate (HD). All patients had severe and complicated CS related to adrenal carcinoma (n = 8) or ectopic ACTH secretion (n = 6). Etomidate was effective in reducing cortisol levels below 500 nmol/L in a median of 1 day in the HD group compared to 3 days in the LD group (P = 0.013). However, all patients of the HD group had etomidate-induced cortisol insufficiency and needed frequent monitoring, while no patient from the LD group required hydrocortisone supplementation. No patient in either group died from complications of CS or etomidate treatment, but final outcome was poor as six patients in the LD group and all four patients in the HD group died from their cancer during follow-up.

Conclusion

Our study suggests that, for patients with severe CS who do not require intensive organ-supporting therapy, the use of very low doses of etomidate in medical wards should be considered.

Supplementary Materials

    • Supplemental Table S1. Individual characteristics of the 14 patients included in the study, treatments and outcome

 

     European Society of Endocrinology

Sept 2018 onwards Past Year Past 30 Days
Abstract Views 446 446 365
Full Text Views 35 35 26
PDF Downloads 25 25 20
  • 1

    AlexandrakiKIGrossmanAB. Therapeutic strategies for the treatment of severe Cushing’s syndrome. Drugs 2016 76 447458. (https://doi.org/10.1007/s40265-016-0539-6)

    • Search Google Scholar
    • Export Citation
  • 2

    YoungJHaissaguerreMViera-PintoOChabreOBaudinETabarinA. Management of Endocrine Disease: Cushing’s syndrome due to ectopic ACTH secretion: an expert operational opinion. European Journal of Endocrinology 2020 182 R29R58. (https://doi.org/10.1530/EJE-19-0877)

    • Search Google Scholar
    • Export Citation
  • 3

    BaudinE & Endocrine Tumor Board of Gustave Roussy. Adrenocortical carcinoma. Endocrinology and Metabolism Clinics of North America 2015 44 411434. (https://doi.org/10.1016/j.ecl.2015.03.001)

    • Search Google Scholar
    • Export Citation
  • 4

    SchulteHMBenkerGReinweinDSippellWGAllolioB. Infusion of low dose etomidate: correction of hypercortisolemia in patients with Cushing’s syndrome and dose-response relationship in normal subjects. Journal of Clinical Endocrinology and Metabolism 1990 70 14261430. (https://doi.org/10.1210/jcem-70-5-1426)

    • Search Google Scholar
    • Export Citation
  • 5

    BroersenLHAJhaMBiermaszNRPereiraAMDekkersOM. Effectiveness of medical treatment for Cushing’s syndrome: a systematic review and meta-analysis. Pituitary 2018 21 631641. (https://doi.org/10.1007/s11102-018-0897-z)

    • Search Google Scholar
    • Export Citation
  • 6

    DanielEAylwinSMustafaOBallSMunirABoelaertKChortisVCuthbertsonDJDaousiCRajeevSP Effectiveness of metyrapone in treating Cushing’s syndrome: a retrospective multicenter study in 195 patients. Journal of Clinical Endocrinology and Metabolism 2015 100 41464154. (https://doi.org/10.1210/jc.2015-2616)

    • Search Google Scholar
    • Export Citation
  • 7

    PredaVASenJKaravitakiNGrossmanAB. Etomidate in the management of hypercortisolaemia in Cushing’s syndrome: a review. European Journal of Endocrinology 2012 167 137143. (https://doi.org/10.1530/EJE-12-0274)

    • Search Google Scholar
    • Export Citation
  • 8

    CarrollTBPeppardWJHerrmannDJJavorskyBRWangTSPatelHZarneckiKFindlingJW. Continuous etomidate infusion for the management of severe Cushing syndrome: validation of a standard protocol. Journal of the Endocrine Society 2019 3 112. (https://doi.org/10.1210/js.2018-00269)

    • Search Google Scholar
    • Export Citation
  • 9

    SohLMGunganahKAkkerSAJonesPKhachiHDodzoKDrakeWM. Etomidate in the emergency management of hypercortisolemia. European Journal of Endocrinology 2012 167 727728; author reply 729. (https://doi.org/10.1530/EJE-12-0698)

    • Search Google Scholar
    • Export Citation
  • 10

    SmithGNielsenM. ABC of intensive care. Criteria for admission. BMJ 1999 318 15441547. (https://doi.org/10.1136/bmj.318.7197.1544)

  • 11

    KardalasEPaschouSAAnagnostisPMuscogiuriGSiasosGVryonidouA. Hypokalemia: a clinical update. Endocrine Connections 2018 7 R135R146. (https://doi.org/10.1530/EC-18-0109)

    • Search Google Scholar
    • Export Citation
  • 12

    HarknessWWattsPKopsteinMDziadkowiecOHicksGScherbakD. Correcting hypokalemia in hospitalized patients does not decrease risk of cardiac arrhythmias. Advances in Medicine 2019 2019 4919707. (https://doi.org/10.1155/2019/4919707)

    • Search Google Scholar
    • Export Citation
  • 13

    DoenickeARoizenMFNebauerAEKuglerAHoerneckeRBeger-HintzenH. A comparison of two formulations for etomidate, 2-hydroxypropyl-β-cyclodextrin (HPCD) and propylene glycol. Anesthesia and Analgesia 1994 79 933939. (https://doi.org/10.1213/00000539-199411000-00020)

    • Search Google Scholar
    • Export Citation
  • 14

    MonaghanPJOwenLJTrainerPJBrabantGKeevilBGDarbyD. Comparison of serum cortisol measurement by immunoassay and liquid chromatography-tandem mass spectrometry in patients receiving the 11β-hydroxylase inhibitor metyrapone. Annals of Clinical Biochemistry 2011 48 441446. (https://doi.org/10.1258/acb.2011.011014)

    • Search Google Scholar
    • Export Citation